Gynoid Fat Distribution and Adipocyte Trapping May Explain Virological Failure With Intramuscular Long-Acting Cabotegravir and Rilpivirine.

HIV infection adipocyte trapping gynecoid fat distribution intramuscular long-acting antiretroviral drugs virological failure

Journal

Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045

Informations de publication

Date de publication:
May 2023
Historique:
received: 01 02 2023
accepted: 17 04 2023
medline: 22 5 2023
pubmed: 22 5 2023
entrez: 22 5 2023
Statut: epublish

Résumé

Intramuscular long-acting antiretroviral drugs can improve adherence to lifelong antiretroviral treatment. Nevertheless, adipose tissue thickness and distribution play a critical role with injectable drugs. We describe a virological failure with cabotegravir and rilpivirine in a Black African woman with human immunodeficiency virus type 1 with gynoid fat distribution (ie, adipose tissue prevailing in the pelvis and hip area) and body mass index <30 kg/m

Identifiants

pubmed: 37213429
doi: 10.1093/ofid/ofad217
pii: ofad217
pmc: PMC10199109
doi:

Types de publication

Journal Article

Langues

eng

Pagination

ofad217

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Déclaration de conflit d'intérêts

Potential conflicts of interest. All authors: No potential conflicts.

Références

HIV Med. 2020 Nov;21(10):617-624
pubmed: 32885559
Eur J Radiol. 2006 Jun;58(3):480-4
pubmed: 16495027
N Engl J Med. 2020 Mar 19;382(12):1124-1135
pubmed: 32130806
N Engl J Med. 2020 Mar 19;382(12):1112-1123
pubmed: 32130809
Clin Pharmacokinet. 2021 Jul;60(7):835-853
pubmed: 33830459
AIDS. 2002 Dec 6;16(18):2419-24
pubmed: 12461415
AIDS. 2021 Jul 15;35(9):1333-1342
pubmed: 33730748
Clin Pharmacol Ther. 2014 Sep;96(3):314-23
pubmed: 24862215

Auteurs

Isabelle de Malliard (I)

Department of Clinical Immunology and Infectious Diseases, Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris, Créteil, France.

Anne-Laure Houist (AL)

Department of Clinical Immunology and Infectious Diseases, Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris, Créteil, France.

Gilles Peytavin (G)

Infection Antimicrobials Modelling Evolution, Inserm, Université de Paris, Paris, France.
Laboratoire de Pharmacologie-Toxicologie, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat Claude Bernard, Paris, France.

Thomas L'Yavanc (T)

Posthospitalization and Rehabilitation Unit, Hôpital Jean Jaurés, Paris, France.

Magali Bouvier (M)

Department of Virology, Henri Mondor Hospital, Créteil, France.

Pierre Cappy (P)

Department of Virology, Henri Mondor Hospital, Créteil, France.

Jean-Daniel Lelièvre (JD)

Department of Clinical Immunology and Infectious Diseases, Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris, Créteil, France.
Vaccine Research Institut, Inserm U955 Equipe 16, Université Paris Est Créteil, Créteil, France.

Elsa Feredj (E)

Department of Clinical Immunology and Infectious Diseases, Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris, Créteil, France.

William Vindrios (W)

Department of Clinical Immunology and Infectious Diseases, Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris, Créteil, France.

Sebastien Gallien (S)

Department of Clinical Immunology and Infectious Diseases, Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris, Créteil, France.

Giovanna Melica (G)

Department of Clinical Immunology and Infectious Diseases, Henri Mondor Hospital, Assistance Publique-Hôpitaux de Paris, Créteil, France.

Classifications MeSH